Cytological examination in the diagnosis of precursor lesions and endometrial cancer: single-center, cross-sectional, blind, controlled, non-randomized study

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Separate diagnostic curettage with material is obtained for histological examination is an invasive procedure with a number of surgical and anesthetic risks. In this regard, the cytological method of endometrial examination, due to the possibility of minimizing the associated risks and the high potential for diagnostic information, is of interest to improve.

AIM: To improve the cytological diagnosis of precancerous diseases and endometrial cancer.

MATERIALS AND METHODS: The study included 136 patients aged 22–79 years with endometrial pathology who underwent examination and treatment in medical institutions in Moscow in the period from 2019 to 2023. All patients underwent surgical treatment in the volume of hysteroscopy with separate diagnostic curettage or hysterectomy, and material from the endometrium was obtained for morphological examination. For cytological examination, the surface of the endometrium or a smear imprint of endometrial tissue were used. For immunocytochemical studies of the expression of p53, PTEN, p63 and CEA markers, 20 samples with endometrial hyperplasia without atypia, 22 samples with endometrioid adenocarcinoma and 5 endometrial samples with atypical hyperplasia were selected. The findings were compared with the results of histological examination and the diagnostic information content of traditional cytology, liquid cytology and their combination was evaluated. Statistical processing of the study results was carried out to generally methods using the StatTech v. 2.6.2 package (Stattech LLC, Russia).

RESULTS: The study revealed a correlation (Pearson chi-squared criterion) between the results of histological examination of the endometrium and liquid cytology, as well as the results of histological examination and traditional cytology (for all indicators p <0.0001). A statistically significant difference in the values of CEA expression in endometrial cells ( p =0.0311) was obtained in the groups of patients with endometrial hyperplasia without atypia, with atypical endometrial hyperplasia and with endometrial adenocarcinoma. The sensitivity and specificity of traditional cytology in detecting endometrial hyperplasia without atypia amounted to 68.4 and 81.7%, liquid cytology — 61.8 and 88.3%, and with the combined use of two cytological methods — 73.7 and 88.3%, respectively. The sensitivity and specificity of traditional and liquid cytology in the detection of atypical endometrial hyperplasia and endometrial adenocarcinoma reached 100 and 97.5%, respectively.

CONCLUSION: The combined use of traditional and liquid cytology expands the possibilities of diagnosing pathological conditions of the endometrium. The significance of the use of the CEA marker in immunocytochemical examination for the diagnosis of endometrial adenocarcinoma has been confirmed.

Full Text

Restricted Access

About the authors

Asel E. Karpova

Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children

Author for correspondence.
Email: aselique@gmail.com
ORCID iD: 0000-0003-3415-8183
SPIN-code: 7732-7663

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

Irina P. Shabalova

Russian Medical Academy of Continuous Professional Education

Email: irenshab@inbox.ru
ORCID iD: 0000-0002-7838-6279
SPIN-code: 7390-0085

MD, Dr. Sci. (Medicine)

Russian Federation, Moscow

Larisa G. Sozaeva

Russian Medical Academy of Continuous Professional Education

Email: sozaewa@mail.ru
ORCID iD: 0000-0002-1793-5684
SPIN-code: 5452-8168

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

Mikhail A. Godkov

Russian Medical Academy of Continuous Professional Education; Sklifosovsky Research Institute for Emergency Medicine

Email: mgodkov@yandex.ru
ORCID iD: 0000-0001-9612-6705
SPIN-code: 4871-6150

MD, Dr. Sci. (Medicine)

Russian Federation, Moscow

References

  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. doi: 10.3322/caac.21834
  2. Kaprin AD, Starinskii VV, Shakhzadova AO. The state of oncological care for the Russian population in 2022. Moscow: MNIOI im. P.A. Gertsena − filial FGBU “NMITs radiologii” Minzdrava Rossii; 2023. (In Russ.)
  3. Nechushkina VM, Den’gina NV, Kolomiets LA, et al. Practice Guidelines for the Treatment of Uterine Carcinoid Cancer and Uterine Sarcomas. Zlokachestvennye opukholi. 2018;8(3s2):190–203. (In Russ.) EDN: QCNKRM doi: 10.18027/2224-5057-2018-8-3S2-190-203
  4. Zinovieva OS, Motovilova TM, Kachalina TS, et al The study of proliferative potential of hypoplastic endometrium with the use of fluorescent immunocytochemistry method in the case of women patients having reproductive disorders in anamnesis. Meditsinskii al’manakh. 2017;(6):84–87. EDN: ZSMOHD
  5. Shinagawa A, Kurokawa T, Yamamoto M, et al. Evaluation of the benefit and use of the new terminology in endometrial cytology reporting system. Diagnost Cytopathol. 2018;46(4):314–319. doi: 10.1002/dc.23901
  6. Fulciniti F, Yanoh K, Karakitsos P, et al. The Yokohama system for reporting directly sampled endometrial cytology: the quest to develop a standardized terminology. Diagnostic C ytopathology. 2018;46(5):400–412. doi: 10.1002/dc.23916
  7. Koleva NN. Diagnosis of cervical cancer by cytologic examination (standard pap test and liquid oncocytology). Kontseptsii fundamental’nykh i prikladnykh nauchnykh issledovanii: sbornik statei Mezhdunarodnoi nauchno-prakticheskoi konferentsii. 2018:145–147. EDN: YQMQQK
  8. Wang Q, Wang Q, Zhao L, et al. Endometrial Cytology as a Method to Improve the Accuracy of Diagnosis of Endometrial Cancer: Case Report and Meta-Analysis. Frontiers in Oncology. 2019;(9):256. doi: 10.3389/fonc.2019.00256
  9. Yanaki F, Hirai Y, Sakamoto K, et al. Liquid-based endometrial cytology using SurePath™ is not inferior to suction endometrial tissue biopsy for detecting endometrial malignancies: Midterm report of a multicenter study advocated by Japan Association of Obstetricians and Gynecologists. Cytopathology. 2019;30(2):223–228. doi: 10.1111/cyt.12657
  10. Yang X. Liquid-based endometrial cytology associated with curettage in the investigation of endometrial carcinoma in a population of 1987 women. Archives of Gynecology and Obstetrics. 2017;296:99–105. doi: 10.1159/000455890
  11. Yanaki F, Hirai Y, Hanada A, et al. Liquid-based endometrial cytology using SurePath™ is not inferior to suction endometrial tissue biopsy in clinical performance for detecting endometrial cancer including atypical endometrial hyperplasia. Acta Cytol. 2017;61(2):133–139. doi: 10.1159/000455890
  12. Wang Q, Wang Q, Zhao L, et al. Endometrial Cytology as a Method to Improve the Accuracy of Diagnosis of Endometrial Cancer: Case Report and Meta-Analysis. Frontiers in Oncology. 2019;9:256. doi: 10.3389/fonc.2019.00256
  13. Yang X, Ma K, Chen R, et al. Liquid-based endometrial cytology associated with curettage in the investigation of endometrial carcinoma in a population of 1987 women. Archives of Gynecology and Obstetrics. 2017;296(1):99–105. doi: 10.1007/s00404-017-4400-2
  14. Jambhekar NA, Chaturvedi AC, Madur BP. Immunohistochemistry in surgical pathology practice a current perspective of a simple, powerful, yet complex, tool. Indian J Pathol Microbiol. 2008;51(1):2–11. doi: 10.4103/0377-4929.40382
  15. Murali R, Davidson B, Fadare O, et al. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. Int J Gynecol Pathol. 2019;38S1(1S1):S40–S63. doi: 10.1097/PGP.0000000000000491
  16. Esmaieli HA, Amidfar H, Mostafidi E, et al. Study on the prognostic value of p53 and PTEN immunomarkers for endometrial cancer using immunohistochemistry. J Anal Res Clin Med. 2017;5(4):112–117. doi: 10.15171/jarcm.2017.022
  17. Mao TL, Ayhan A, Kuo KT, et al. Immunohistochemical study of endometrial high-grade endometrioid carcinoma with or without a concurrent low-grade component: Implications for pathogenetic and survival differences. Histopathology. 2015;67(4):474–482. doi: 10.1111/his.12664
  18. Holtz D, Ramondetta LM, Burke TW, et al. PTEN expression in tamoxifen-associated endometrial cancers. Anticancer Res. 2002;22(5):2945–2948.
  19. Kuhn E, Ayhan A. Diagnostic immunohistochemistry in gynecological neoplasia: a brief survey of the most common scenarios. BMP. 2018;(71):98–109. doi: 10.1136/jclinpath-2017-204787

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Endometrium without morphologic pathology: a — a stratum of endometrial cells of cuboidal shape. Conventional cytology, Romanovsky–Giemsa staining (×400); b — honeycomb-like structure of endometrial cells, liquid-based cytology (ClearPrep). Papanicolaou staining (×400).

Download (216KB)
3. Fig. 2. Endometrial hyperplasia without atypia: a — extensive multilayered stratum of endometrial epithelial cells. Conventional cytology, Romanovsky–Giemsa staining (×400); b — endometrial hyperplasia without atypia. Endometrial cells in dense clusters with cell piling. Liquid-based cytology (ClearPrep). Papanicolaou staining (×400).

Download (289KB)
4. Fig. 3. Endometrioid adenocarcinoma: a — cells are arranged in «spreading» structures. Conventional cytology, Romanovsky–Giemsa staining (×200); b — papilla-like structure, expressed polymorphism of cells and nuclei. Liquid-based cytology (ClearPrep). Papanicolaou staining (×200).

Download (222KB)
5. Fig. 4. Endometrioid adenocarcinoma. Positive cytoplasmic expression of CEA (×200).

Download (175KB)
6. Fig. 5. Endometrioid adenocarcinoma. Positive nuclear expression of p53 (×200).

Download (192KB)

Copyright (c) 2023 Karpova A.E., Shabalova I.P., Sozaeva L.G., Godkov M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:  ПИ № ФС 77 - 86785 от 05.02.2024 (ранее — ПИ № ФС 77 - 59057 от 22.08.2014).